Myelodysplasia-therapeutics response to novel therapy and the need for new diagnostic groups

Leukemia

Volumn 17, Issue 6, 2003, Pages 1183-1185

  Schiller, G J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; AZACITIDINE; CYTOTOXIC AGENT; DNA METHYLTRANSFERASE; ERYTHROPOIETIN; IMMUNOMODULATING AGENT; PREDNISONE; THALIDOMIDE; THYMOCYTE ANTIBODY; TOPOTECAN; ANTINEOPLASTIC AGENT;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOGENETICS; DIAGNOSTIC PROCEDURE; DNA METHYLATION; DOSE RESPONSE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MYELODYSPLASIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REGULATORY MECHANISM; TREATMENT PLANNING; CELL TRANSFORMATION; CLASSIFICATION; DRUG EFFECT; MYELODYSPLASTIC SYNDROME; REVIEW;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 0037702811     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402939     Document Type: Article

References (17)

1. Rosati S, Anastasi J, Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin Hematol 1996; 33: 111-126.
2. Bartl R, Frisch B, Baumgart R. Morphological classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies. Leukemia Res 1992; 16: 15-33.
3. Kouides PA, Bennett JM. Morphology and classification of myelodysplastic syndrome. Hematol Oncol Clin North Am 1992; 6: 485-499.
4. Sverre H. Cytogenetic findings in primary and secondary MDS. Leukemia Res 1992; 16: 43-46.
5. Enright H, Miller W. Autoimmune phenomena in patients with myelodysplastic syndromes. Leukemia Lymphoma 1996; 24: 483-489.
6. De Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326-2331.
7. Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet JP et al. Groupe Français des Myélodysplasies (GFM) and Groupe Ouest-Est d'étude des Leucémies aiguës myéldïdes (GOELAMS). A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myclodysplasies, Group Ouest-Est d'etude des Leucemies aigues myeloides. Leukemia 1999; 13: 524-529.
8. De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R et al. For the Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 1997; 90: 3853-3857; abstract.
9. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-965.
10. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002; 16: 1-6.
11. Yoshida Y, Nakahata T, Shibata A, Takahashi M, Moriyama Y, Kaku K et al. Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. Leukemia and Lymphoma 1995; 18: 457-463.
12. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S et al. Maintenance treatment for the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87: 4076-4081.
13. Beran M, Kantarjian H, O'Brien S, Koller C, Al-Bitar M, Arbuck S et al. Topotecan, a topoisomerase i inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473-2479; abstract.
14. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2 002; 137: 15 6-163.
15. Silverman LR, Demakon EP, Peterson BL, Korblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Onc 2002; 20: 2429-2440.
16. Donelli A, Chiodino C, Panissidi T, Roncaglia R, Torelli G. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?. Haematologica 2000; 85: 1002-1003.
17. van de Vijver MJ, He YD, vat't Veer LJ, Dai H, Hart AAM, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Eng J Med 2002; 347: 1999-2009.